NYSEHealth CareMedical DevicesSnapshot 2026-07-23
Reading INSP? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround opportunity. The company has shown strong recent financial performance but faces ongoing challenges with coding and reimbursement uncertainty, which could impact future growth.
The market appears to have priced in a level of fragility due to weak execution quality, but the valuation remains justified as INSP is considered cheap compared to its peers. There is a notable expectations gap, indicating that the market may not fully reflect potential improvements.
Management's execution on revenue guidance and operating margins is mixed, with limited progress against prior expectations. Near-term risks are elevated, but the probability of missing guidance is relatively low, suggesting some stability in performance.
The long-term thesis hinges on whether INSP can resolve its coding and reimbursement issues and achieve its revenue targets. Additionally, the performance of sector bellwethers like ABT, SYK, and MDT will be crucial in determining if the healthcare sector tailwind continues.
Over the next 1 to 3 years, INSP's success will depend on management's ability to navigate current challenges and capitalize on sector momentum. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'mixed' to 'mild_favorable'.
Yes, our read has strengthened. This improvement is driven by the latest earnings beat, which indicates strong financial performance and supports the thesis that the reasons to own the stock remain intact. There are no current threats noted that would weaken this outlook.
as of 2026-07-23
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Resolving coding issues is key for revenue growth. It affects how doctors get paid for procedures.
Confirms:A new CPT code for Inspire V has been announced. This will help with reimbursement.
Disproves:There are delays in coding updates. This makes it harder to get reimbursement for Inspire V.
Why it matters: If revenue growth drops below its median, it may signal broader issues in the healthcare sector.
Confirms:Healthcare sector revenue growth drops below 1% year over year.
Disproves:Healthcare sector revenue growth remains above 1% year over year.
Why it matters: Better revenue growth means more market share and fixing coding problems.
Confirms:Q2 revenue growth reported above 1.6% compared to Q2 2025.
Disproves:Q2 revenue growth reported below 1.6% compared to Q2 2025.
Why it matters: Meeting or beating EPS goals shows good cost control and revenue. This boosts investor trust.
Confirms:Adjusted diluted EPS reaches at least $0.07 in Q2.
Disproves:Adjusted diluted EPS falls below $0.07 in Q2.
Why it matters: Hitting revenue goals is key to rebuild investor trust after a drop in Q1.
Confirms:Q2 revenue was over $204.6 million, showing growth towards the yearly goal of $825M to $875M.
Disproves:Q2 revenue is below $204.6 million, showing ongoing problems in reaching growth.
Why it matters: Resolving this uncertainty is key to revenue growth. It impacts how doctors bill for the Inspire V system.
Confirms:A formal announcement will bring new coding rules. These rules will help payments for Inspire V cases.
Disproves:Delays or unclear information on coding and payments for Inspire V continue.
Why it matters: A higher margin shows better cost control and efficiency. This is key for making money.
Confirms:Adjusted operating margin was at or above 2% for Q2.
Disproves:The operating margin was less than 2% for Q2.
Why it matters: The new director's experience may change company choices and plans.
Confirms one read:A new board member with industry experience has been announced.
Confirms the other:No announcement of a new board member within the next quarter.
